<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

HUB Organoids: Top 9 Technical Questions

sylvia boj, scientific director of HUB answers HUB Organoid technical questions

sylvia boj, scientific director of HUB answers HUB Organoid technical questionsReview the top 9 technical questions on HUB organoid development from our recent webinar, answered by Dr Sylvia Boj, Scientific Director of Hubrecht Organoid Technology (HUB).

Can you Explain How HUB Organoids are Derived?

HUB Organoid establishment from different tissues is explained in multiple publications from our academic group, the Clevers lab, and is also covered in an earlier blog post:

Have you Isolated Adult Stem Cells Other than Intestinal Ones?

We’ve identified Lgr5+ cells with the capacity to generate new cells in liver and pancreas after inducing injury in these tissues.

Other stem cell markers have also been identified, such as:

Can HUB Organoids be Generated from Frozen Tissue?

Yes, organoids can be generated from cryopreserved tissue. The efficiency is lower than using fresh tissue, however, so we only recommend doing this from resected tissue rather than biopsies.

What is a Good Method for Counting Organoids?

We are evaluating several cell counters on the market for organoid counting. Currently, we make a dilution step of organoid suspensions, spreading 10µl of organoid solution to make a long line (rather than a drop) and then count the organoids.

How are HUB Organoids Expanded?

Organoids are expanded by disrupting them into several pieces. This disruption can be:

  • Mechanical - by pipetting them with either low retention tips or glass pipets (though this last technique should only be used when the amount of organoids for disrupting are plated in 200µl of ECM).
  • Tryp-shearing - a mechanical disruption that includes the presence of TrypLE (between 25 and 50% volume).

This last method is recommended for compact organoids that cannot be disrupted just by shearing. Importantly, we do not trypsinize organoids in the traditional way (100% TryPLE and incubate in a water bath). This is because, for most organoid models, if they reach single cell level only a few cells will grow and generate new organoids.

After disrupting the organoids, they are centrifuged and resuspended in new ECM.

Regarding Expansion - Have You Evaluated the Genetic Profile of Organoids between Passages? What's the Highest Number of Passages You Recommend?

For normal models generated from non-cancerous tissue, organoids have been expanded for a year, being passaged weekly. The accumulation of mutations was comparable to the accumulation of mutations that our somatic cells experience (Huch et al. Cell 2015;(160):299-312; Blokzijl et al. Nature 2016;(7624):260-264).

For cancer models, the intrinsic nature of the tumor is to accumulate more mutations or acquire genomic instability. When generating a new model from isolation or after receiving a cryovial, we always recommended to generate a master cell bank (MCB) and after that a WCB, and thaw the WCB for the experiments.

Dependent on the organoid model, for organoids that are expanded weekly (e.g. intestinal, pancreatic, or liver models) 2-3 months is the average time they can be expanded. For models that are expanded every 15-18 days (breast or lung models) they can be in culture up to 4-5 months.

How do HUB Organoids Change over Passage?

Organoids are susceptible to the quality of growth factors and organoid density in the ECM drop. If media is not refreshed frequently, organoids are plated too crowded (meaning there is not enough signaling to maintain proliferation of all cells) or too diluted, organoid cells can differentiate. This loses proliferative cells and the possibility to expand the organoids.

Can Organoids be Cryo-Preserved after Formation? And then Thawed Later Ready for Immediate Use?

Yes, HUB organoids can be cryopreserved. After thawing, we always recommend at least one passage to let them recover. But if the experiment requires it, the organoids can be used right after thawing. In this case, it’s important to use a good freeze-thaw protocol for organoids to ensure more than 85% viability after thawing.

Can Organoids be used for Organ on a Chip Technologies and Studies?

Yes, HUB is collaborating with some companies to include organoids rather than cell lines in microfluidic plates. So far, we have obtained interesting results with intestinal and kidney organoids.


Related Posts